olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatment
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Recurrent Ovarian Cancer
Conditions
Platinum-resistant Recurrent Ovarian Cancer
Trial Timeline
Nov 26, 2018 → Sep 1, 2022
NCT ID
NCT03699449About olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatment
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatment is a phase 2 stage product being developed by AstraZeneca for Platinum-resistant Recurrent Ovarian Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT03699449. Target conditions include Platinum-resistant Recurrent Ovarian Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03699449 | Phase 2 | UNKNOWN |
Competing Products
16 competing products in Platinum-resistant Recurrent Ovarian Cancer